| scholarly article | Q13442814 |
| P2093 | author name string | E T Yeh | |
| J Chang | |||
| J S Cheng | |||
| J T Willerson | |||
| V Pasceri | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 2531-4 | |
| P577 | publication date | 2001-05-29 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs | |
| P478 | volume | 103 |
| Q43117268 | (-)-epigallocatechin gallate inhibits endothelin-1-induced C-reactive protein production in vascular smooth muscle cells |
| Q42861202 | A Study of Inflammatory Status in Nephropathy Patients with History of Type-II Diabetes Mellitus Undergoing Haemodialysis |
| Q34145748 | A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation |
| Q38020932 | A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. |
| Q50261941 | A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration. |
| Q47953655 | Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. |
| Q37156874 | Acute phase reactants as novel predictors of cardiovascular disease |
| Q37340088 | Aldosterone Receptor Antagonism Reduces Urinary C-Reactive Protein Excretion in Angiotensin II-Infused, Hypertensive Rats |
| Q52558707 | An integrative approach to investigate the association among high-sensitive C-reactive protein, body fat mass distribution, and other cardiometabolic risk factors in young healthy women. |
| Q35050146 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes |
| Q34612908 | Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease |
| Q36025935 | Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2. |
| Q37021297 | Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease |
| Q34644504 | Antiinflammatory and immunomodulatory properties of statins |
| Q46724390 | Antioxidant and anti-inflammatory effects of flavocoxid in high-cholesterol-fed rabbits |
| Q28080148 | Apical Periodontitis - Is It Accountable for Cardiovascular Diseases? |
| Q36623323 | Are there race-dependent endothelial cell responses to exercise? |
| Q36681844 | Arterial ageing |
| Q28196404 | Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells |
| Q43580765 | Association of elevated inflammatory and endothelial biomarkers with prehypertension among Mongolians in China |
| Q48439260 | Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea |
| Q84430476 | Atherosclerosis risk factors in systemic lupus erythematosus |
| Q43194538 | Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway |
| Q37192660 | Bench-to-bedside review: the value of cardiac biomarkers in the intensive care patient. |
| Q38472979 | Biological actions of pentraxins |
| Q34697950 | Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives |
| Q88189869 | C reactive protein and long-term risk for chronic kidney disease: a historical prospective study |
| Q43013486 | C reactive protein and microvascular function |
| Q79203598 | C-Reactive Protein Directly Inhibits Nitric Oxide Production by Cytokine-stimulated Vascular Smooth Muscle Cells |
| Q36460995 | C-reactive Protein as a Potential Biomarker of Residual Obstructive Sleep Apnea Following Adenotonsillectomy in Children |
| Q28200344 | C-reactive protein (CRP)-lowering agents |
| Q35558796 | C-reactive protein and atherothrombosis—Beyond a biomarker: an actual partaker of lesion formation |
| Q35562701 | C-reactive protein and cardiovascular disease: new insights from an old molecule |
| Q50778192 | C-reactive protein and coronary composition in patients with percutaneous revascularization. |
| Q36014794 | C-reactive protein and end-stage renal disease |
| Q38514723 | C-reactive protein and inflammation: conformational changes affect function. |
| Q28195425 | C-reactive protein and other inflammatory risk markers in acute coronary syndromes |
| Q35197097 | C-reactive protein and risk of cardiovascular disease: evidence and clinical application |
| Q46640342 | C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy |
| Q42489262 | C-reactive protein contributes to the hypercoagulable state in coronary artery disease. |
| Q44445811 | C-reactive protein correlates with macrophage accumulation in coronary arteries of hypercholesterolemic pigs |
| Q46653379 | C-reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease. |
| Q38596519 | C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance |
| Q48450100 | C-reactive protein in children with obstructive sleep apnea and the effects of treatment |
| Q35997686 | C-reactive protein in end-stage renal disease: are there reasons to measure it? |
| Q45065931 | C-reactive protein increases oxygen radical generation by neutrophils |
| Q53615277 | C-reactive protein induces NF-kappaB activation through intracellular calcium and ROS in human mesangial cells. |
| Q54452058 | C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. |
| Q54439738 | C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. |
| Q44142467 | C-reactive protein promotes adhesion of monocytes to endothelial cells via NADPH oxidase-mediated oxidative stress |
| Q39509248 | C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes |
| Q40248704 | C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy |
| Q35585938 | C-reactive protein, inflammation, and coronary risk: an update |
| Q38912823 | C-reactive protein-mediated phagocytosis of Leishmania donovani promastigotes does not alter parasite survival or macrophage responses. |
| Q35558793 | C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? |
| Q35942423 | C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity |
| Q45174694 | C-reactive protein: history and revival |
| Q28194885 | C-reactive protein: the pawn has been promoted to queen |
| Q57417441 | CRPandFCGR2Agenes have an epistatic effect on carotid artery intima-media thickness: the Cardiovascular Risk in Young Finns Study |
| Q24605567 | Cancer cachexia--pathophysiology and management |
| Q37762838 | Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures |
| Q36872073 | Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator |
| Q37139891 | Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke. |
| Q40198989 | Carotid plaque, stroke pathogenesis, and CRP: treatment of ischemic stroke. |
| Q38101728 | Circulating adhesion molecules in obstructive sleep apnea and cardiovascular disease |
| Q39990700 | Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease |
| Q33960827 | Circulating levels of inflammatory markers in intrauterine growth restriction |
| Q36815424 | Combinations of Polymorphic Markers of Chemokine Genes, Their Receptors and Acute Phase Protein Genes As Potential Predictors of Coronary Heart Diseases |
| Q44397609 | Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). |
| Q46914500 | Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia |
| Q37193018 | Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: a hospital-based, prospective study in Greek patients |
| Q35932082 | Correlations between coronary plaque tissue composition assessed by virtual histology and blood levels of biomarkers for coronary artery disease. |
| Q28219483 | Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease |
| Q33918306 | Cross-talk between endothelin-1 and mineral metabolism in hemodialysis patients: a cross-sectional study. |
| Q51718079 | Cytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysis. |
| Q35813707 | DNA methylation in inflammatory genes among children with obstructive sleep apnea |
| Q37994308 | Developing and assessing cardiovascular biomarkers |
| Q37728073 | Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay |
| Q35549901 | Diet and C-reactive protein |
| Q44205536 | Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy |
| Q37941867 | Do statins have a role in reduction/prevention of post-PCI restenosis? |
| Q36403750 | Does C-reactive protein contribute to atherothrombosis via oxidant-mediated release of pro-thrombotic factors and activation of platelets? |
| Q38333277 | Effect of C-reactive protein on gene expression in vascular endothelial cells |
| Q41971745 | Effect of CRP on Some of the in vitro Physicochemical Properties of LDL |
| Q55417016 | Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis. |
| Q42167510 | Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction |
| Q43191149 | Effect of tocopheryl phosphate on key biomarkers of inflammation: Implication in the reduction of atherosclerosis progression in a hypercholesterolaemic rabbit model. |
| Q33633640 | Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin |
| Q50849393 | Effects of a short term supplementation of a fermented papaya preparation on biomarkers of diabetes mellitus in a randomized Mauritian population. |
| Q34255336 | Effects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme oxygenase-1 in healthy human subjects |
| Q44447370 | Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. |
| Q44960162 | Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease |
| Q36359547 | Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article |
| Q43076575 | Effects of partially hydrogenated, semi-saturated, and high oleate vegetable oils on inflammatory markers and lipids |
| Q36216863 | Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease |
| Q47993128 | Efficacy of lycopene on modulation of renal antioxidant enzymes, ACE and ACE gene expression in hyperlipidaemic rats |
| Q34947183 | Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor |
| Q38930169 | Elevations in C-reactive protein and endothelin-1 system activity in humans. |
| Q34655075 | Endothelial dysfunction in insulin resistance and type 2 diabetes |
| Q73734669 | Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden |
| Q36256278 | Endothelial function and inflammation in coronary artery disease |
| Q35172201 | Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention |
| Q34340622 | Evidence for C-reactive protein's role in (CRP) vascular disease: atherothrombosis, immuno-regulation and CRP. |
| Q35847531 | Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis |
| Q36357402 | Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q33485550 | Functional analysis of the C-reactive protein (CRP) gene -717A>G polymorphism associated with coronary heart disease |
| Q39954815 | G-CSF exerts dual effects on endothelial cells--opposing actions of direct eNOS induction versus indirect CRP elevation. |
| Q37411250 | Gemfibrozil, stretching arms beyond lipid lowering |
| Q40502458 | Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones |
| Q55332127 | Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients. |
| Q55967625 | HIV-1 and the macrophage |
| Q37586444 | Harnessing the early post-injury inflammatory responses for cardiac regeneration |
| Q36077858 | High sensitivity C-reactive protein in clinical practice |
| Q34973446 | High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment |
| Q44588136 | High-dose biotin may down-regulate hepatic expression of acute phase reactants by mimicking the physiological role of nitric oxide |
| Q37980496 | High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? |
| Q36297402 | High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. |
| Q33798161 | Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response |
| Q47215721 | Hs-CRP is associated with weight, BMI, and female sex but not with endothelial function in children with type 1 diabetes. |
| Q34375542 | Hypercholesterolemia and microvascular dysfunction: interventional strategies |
| Q46558389 | Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome |
| Q47209180 | Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation |
| Q36116347 | Inflammation and its association with glucose disorders and cardiovascular disease |
| Q37923226 | Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy--evidence from clinical studies |
| Q47437758 | Inflammation as a therapeutic target: a unique role for abciximab |
| Q36410507 | Inflammation in end-stage renal disease: the hidden enemy |
| Q36202581 | Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists |
| Q36333915 | Inflammation, thrombosis and acute coronary syndromes |
| Q34941391 | Inflammatory bio-markers and cardiovascular risk prediction |
| Q42686418 | Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy |
| Q46426580 | Inflammatory markers in women with a recent history of gestational diabetes mellitus |
| Q34428150 | Inflammatory pathways in atherosclerosis and acute coronary syndromes |
| Q33229109 | Inflammatory protein profile during systemic high dose interleukin-2 administration |
| Q34225645 | Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance |
| Q37049390 | Interactions between chronic renal disease and periodontal disease |
| Q37310466 | Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis |
| Q57635851 | Is inflammation the critical factor linking vulnerable coronary plaques to clinicalcoronary disease? |
| Q35622165 | Leukocytes and coronary heart disease |
| Q79321985 | Lipoprotein (a) and acute-phase response in patients with vestibular neuronitis |
| Q44967456 | Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. |
| Q28583733 | Long-term ethanol consumption initiates atherosclerosis in rat aorta through inflammatory stress and endothelial dysfunction |
| Q35810903 | Low Plasma Hdl Cholesterol and Elevated C Reactive Protein further Increase Cardiovascular Disease Risk in Latinos with Type 2 Diabetes |
| Q44914830 | Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy |
| Q54388725 | Low-level C-reactive protein levels exert cytoprotective actions on human podocytes. |
| Q53621412 | Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL. |
| Q34820339 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia |
| Q44742540 | Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia |
| Q89965680 | Monomeric C-Reactive Protein in Serum With Markedly Elevated CRP Levels Shares Common Calcium-Dependent Ligand Binding Properties With an in vitro Dissociated Form of C-Reactive Protein |
| Q47892221 | Morning levels of C-reactive protein in children with obstructive sleep-disordered breathing |
| Q33992611 | Myeloid-derived suppressor cells are involved in lysosomal acid lipase deficiency-induced endothelial cell dysfunctions |
| Q36576558 | New anti-inflammatory agents to reduce atherosclerosis |
| Q53600984 | Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. |
| Q35090367 | Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction |
| Q37872190 | No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease |
| Q33984026 | Novel markers of peripheral arterial disease |
| Q37802303 | Obesity and obstructive sleep apnea syndrome in children: a tale of inflammatory cascades |
| Q28554387 | Obstructive Sleep Apnea Is Associated with Elevated High Sensitivity C-Reactive Protein Levels Independent of Obesity: Korean Genome and Epidemiology Study |
| Q30448403 | Obstructive sleep apnea in children: a critical update |
| Q34313304 | Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. |
| Q36154953 | PPARalpha in atherosclerosis and inflammation |
| Q24642728 | PPARs and the cardiovascular system |
| Q37790384 | PPARs as therapeutic targets in cardiovascular disease |
| Q49953684 | PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma. |
| Q54654762 | Palmitate induces C-reactive protein expression in human aortic endothelial cells. Relevance to fatty acid–induced endothelial dysfunction |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q35088060 | Pathogenetic concepts of acute coronary syndromes |
| Q37565305 | Periodontal disease and risk of atherosclerotic coronary heart disease |
| Q51360578 | Periodontal inflammatory burden correlates with C-reactive protein serum level. |
| Q35940672 | Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications |
| Q36012223 | Picolinic acid in patients with chronic hepatitis C infection: a preliminary report |
| Q36569766 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects |
| Q44816834 | Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation |
| Q40565085 | Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. |
| Q36974692 | Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients |
| Q44574645 | Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients |
| Q38438066 | Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication |
| Q54338964 | Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cells. |
| Q37709401 | Predictive value of C-reactive protein after drug-eluting stent implantation |
| Q36624223 | Present and future biochemical markers for detection of acute coronary syndrome |
| Q83194887 | Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP |
| Q36014621 | Protection from Metabolic Dysregulation, Obesity, and Atherosclerosis by Citrus Flavonoids: Activation of Hepatic PGC1α-Mediated Fatty Acid Oxidation |
| Q46532499 | Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage |
| Q34114355 | Protein targets of inflammatory serine proteases and cardiovascular disease |
| Q44413736 | Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway |
| Q36591722 | Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? |
| Q36134214 | Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis |
| Q28196720 | Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels |
| Q37200278 | Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells |
| Q36238935 | Resveratrol, wine, and atherosclerosis |
| Q46738580 | Retinol-binding protein, transthyretin, and C-reactive protein in extremely low birth weight (ELBW) infants |
| Q54225675 | Role of C-Reactive Protein at Sites of Inflammation and Infection. |
| Q35213253 | Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis |
| Q35042927 | Role of C-reactive protein in the assessment of cardiovascular risk |
| Q36771454 | Role of biomarkers in developing new therapies for vascular disease |
| Q33352994 | Role of inflammation in the pathogenesis of arterial stiffness |
| Q30310670 | Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes |
| Q33556796 | Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT) |
| Q34290152 | Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway |
| Q53594601 | Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. |
| Q36385157 | Serum amyloid A: the "other" inflammatory protein |
| Q33642223 | Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population |
| Q36229625 | Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man |
| Q24813777 | Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey |
| Q64086780 | Sodium thiocyanate treatment attenuates atherosclerotic plaque formation and improves endothelial regeneration in mice |
| Q24541529 | Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis |
| Q86415237 | Spironolactone improves endothelial dysfunction in ankylosing spondylitis |
| Q40738275 | Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders. |
| Q34482145 | Statins and inflammatory markers |
| Q36797719 | Statins and sepsis: multiple modifications at multiple levels. |
| Q37741869 | Statins and their role in pre-percutaneous coronary intervention. |
| Q36382202 | Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? |
| Q46158768 | Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes |
| Q37071609 | Sulforaphane attenuates the development of atherosclerosis and improves endothelial dysfunction in hypercholesterolemic rabbits |
| Q60492192 | Systemic inflammation in nonischemic dilated cardiomyopathy |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q35913219 | Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy |
| Q26999377 | Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes |
| Q60955111 | The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases |
| Q92445757 | The Multiple Faces of C-Reactive Protein-Physiological and Pathophysiological Implications in Cardiovascular Disease |
| Q37337997 | The Role of PPARs in the Endothelium: Implications for Cancer Therapy |
| Q33354913 | The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations |
| Q35999439 | The connection between C-reactive protein and atherosclerosis |
| Q46958876 | The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women. |
| Q89430484 | The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. A case - control study |
| Q37144130 | The evolving role of C-reactive protein in atherothrombosis |
| Q34898069 | The macrophage: the intersection between HIV infection and atherosclerosis. |
| Q36496252 | The pathobiology of the vessel wall: implications for imaging |
| Q35954117 | The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients |
| Q36703970 | The periodontal host response with diabetes |
| Q36430041 | The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant? |
| Q42844903 | The relationship between osteopontin and adiponectin in patients with essential hypertension |
| Q33773157 | The role of CRP and inflammation in the pathogenesis of age-related macular degeneration. |
| Q34838209 | The role of PPARs in atherosclerosis |
| Q28193154 | The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease |
| Q37939658 | The role of monocytes and inflammation in the pathophysiology of heart failure |
| Q36405110 | The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis |
| Q83292670 | Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities |
| Q35771582 | Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins |
| Q36025968 | Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk |
| Q36894180 | Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. |
| Q34567958 | Vascular effects of TZDs: new implications |
| Q38365338 | What can blood biomarkers tell us about cardiovascular risk in obstructive sleep apnea? |
Search more.